Defendant

Amneal

1 case as defendant.

Cases
1
Active
1
0 closed
Filed
—
Top venue
N.D. California
1 case

Company profile

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), commonly called Amneal, is a diversified global biopharmaceutical company headquartered in Bridgewater, New Jersey. It was founded in 2002 by brothers Chirag and Chintu Patel and went public in 2018 via a combination with Impax Laboratories (the combined entity was originally incorporated as Atlas Holdings, Inc.). It is a public operating company, not a subsidiary. Sources cite roughly 8,500–8,700 employees and net revenue of about $2.8 billion (FY2024) and $3.0 billion (FY2025), with three reporting segments.

Products and operations. Amneal develops, manufactures, markets, and distributes medicines, primarily in the U.S., India, and Ireland. Its Affordable Medicines segment covers retail generics, institutional injectables, and biosimilars (e.g., ALYMSYS, RELEUKO, FYLNETRA, plus approved denosumab biosimilars). Its Specialty segment sells branded CNS and endocrine products, including CREXONT and RYTARY (Parkinson's) and UNITHROID (hypothyroidism). Its AvKARE segment distributes pharmaceuticals to U.S. government, retail, and institutional markets, chiefly the Department of Defense and Veterans Affairs. It operates multiple FDA-registered manufacturing and R&D sites and an in-house API capability.

Patent-litigation posture. In the tracked data, Amneal appears once and only as a defendant — zero plaintiff cases — consistent with an operating company being named in litigation rather than an entity asserting patents. The sole tracked matter sits in the U.S. District Court for the Northern District of California, not a plaintiff-friendly venue like the Eastern District of Texas.

Notable case. The single tracked appearance is In re Xyrem (Sodium Oxybate) Antitrust Litigation (N.D. Cal.), where Amneal is a defendant. This MDL concerns allegations over the branded Xyrem (sodium oxybate) market and generic entry/settlement conduct; Amneal's involvement relates to its oxybate-related activities. Note this is an antitrust matter rather than a patent-infringement assertion, and the case list does not establish its procedural posture or any merits outcome. No other litigation appearances are recorded in the dataset.

Sources: Amneal fact sheet and FY2025 Form 10-K (amneal.com, SEC EDGAR); Nasdaq/Yahoo Finance company profiles.

In re Xyrem (Sodium Oxybate) Antitrust Litigation

ongoing; trial set May 19, 2025; settlements with Amneal and Lupin final approval April 17, 2024
Patents:8589182

Consolidated MDL antitrust litigation concerning Xyrem (sodium oxybate). U.S. 8,589,182 is listed among the patents cited/at issue. Class certification and summary-judgment motions have been decided; trial set for May 19, 2025.